Literature DB >> 25025444

A novel chromogenic in situ hybridization assay for FGF23 mRNA in phosphaturic mesenchymal tumors.

Jodi M Carter1, Bolette L Caron, Ahmet Dogan, Andrew L Folpe.   

Abstract

Phosphaturic mesenchymal tumors of the mixed connective tissue type (PMT) are very rare tumors of bone and soft tissues. Most patients with PMT have long-standing osteomalacia secondary to production of fibroblast growth factor 23 (FGF23), a hormone that inhibits phosphate reuptake within the renal proximal tubule. Previously, we have reported the detection of FGF23 mRNA in PMT by reverse transcription polymerase chain reaction (PCR); however, the low specificity and risk for nontumoral tissue contamination inherent in PCR-based methodology limit its clinical utility. We evaluated RNAscope as a semiquantitative method of in situ FGF23 mRNA detection in the diagnosis of PMT. Twenty-five PMTs (median 52 y, range 5 to 73 y) occurred in patients with tumor-induced osteomalacia (TIO), manifesting as masses (mean 3.9 cm, range 1.4 to 12 cm) in various bones and soft tissues. FGF23 mRNA was positive in 96% (22/23) informative cases of PMT: 16 cases scored 3+; 5 scored as 2+; 1 scored as 1+. Among these cases, FGF23 mRNA was detected in 3 malignant PMTs along with their metastases. Forty control cases included aneurysmal bone cyst (N=4), chondromyxoid fibroma (N=8), high-grade osteosarcomas (N=8), and (nonfamilial) tumoral calcinosis, as well as miscellaneous cartilage-forming tumors or osteoid-forming tumors and soft tissue tumors. All control cases were negative for FGF23 mRNA in the lesional cells. One aneurysmal bone cyst had rare FGF23 mRNA-expressing osteocytes clustered around remodeled bone. One ovarian serous carcinoma in a patient with disseminated disease, elevated serum FGF23, and TIO was negative for FGF23 mRNA in the neoplastic cells. We conclude that RNAscope is a highly sensitive and specific, semiquantitative in situ hybridization method of FGF23 mRNA detection applicable to formalin-fixed, paraffin-embedded tissues. Detection of FGF23 expression is a valuable diagnostic adjunct, especially in patients with occult TIO. Compared with reverse transcription PCR, this method preserves tissue morphology and reduces "false positives" related to detection of endogenous FGF23 mRNA expression by osteocytes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25025444     DOI: 10.1097/PAS.0000000000000290

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  20 in total

Review 1.  [Tumor-induced osteomalacia caused by an FGF23-secreting myopericytoma : Case report and literature review].

Authors:  N Muro Bushart; L Tharun; R Oheim; A Paech; J Kiene
Journal:  Orthopade       Date:  2020-01       Impact factor: 1.087

Review 2.  What is new about the molecular genetics in matrix-producing soft tissue tumors? -The contributions to pathogenetic understanding and diagnostic classification.

Authors:  Yu-Chien Kao; Jen-Chieh Lee; Hsuan-Ying Huang
Journal:  Virchows Arch       Date:  2019-11-07       Impact factor: 4.064

3.  Phosphaturic Mesenchymal Tumor Involving the Head and Neck: A Report of Five Cases with FGFR1 Fluorescence In Situ Hybridization Analysis.

Authors:  Jason K Wasserman; Bibianna Purgina; Chi K Lai; Denis Gravel; Alyssa Mahaffey; Diana Bell; Simion I Chiosea
Journal:  Head Neck Pathol       Date:  2016-01-12

4.  Possibility of D2-40 as a diagnostic and tumor differentiation-suggestive marker for some of phosphaturic mesenchymal tumors.

Authors:  Shogo Tajima; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 5.  Tumor-Induced Osteomalacia.

Authors:  Pablo Florenzano; Iris R Hartley; Macarena Jimenez; Kelly Roszko; Rachel I Gafni; Michael T Collins
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

Review 6.  Phosphaturic mesenchymal tumors: what an endocrinologist should know.

Authors:  J M Boland; P J Tebben; A L Folpe
Journal:  J Endocrinol Invest       Date:  2018-02-14       Impact factor: 4.256

7.  DNAJB1-PRKACA is specific for fibrolamellar carcinoma.

Authors:  Rondell P Graham; Long Jin; Darlene L Knutson; Sara M Kloft-Nelson; Patricia T Greipp; Nina Waldburger; Stephanie Roessler; Thomas Longerich; Lewis R Roberts; Andre M Oliveira; Kevin C Halling; Peter Schirmacher; Michael S Torbenson
Journal:  Mod Pathol       Date:  2015-02-20       Impact factor: 7.842

8.  Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors.

Authors:  Jen-Chieh Lee; Sheng-Yao Su; Chun A Changou; Rong-Sen Yang; Keh-Sung Tsai; Michael T Collins; Eric S Orwoll; Chung-Yen Lin; Shu-Hwa Chen; Shyang-Rong Shih; Cheng-Han Lee; Yoshinao Oda; Steven D Billings; Chien-Feng Li; G Petur Nielsen; Eiichi Konishi; Fredrik Petersson; Thomas O Carpenter; Kesavan Sittampalam; Hsuan-Ying Huang; Andrew L Folpe
Journal:  Mod Pathol       Date:  2016-07-22       Impact factor: 7.842

9.  CD56 may be a more useful immunohistochemical marker than somatostatin receptor 2A for the diagnosis of phosphaturic mesenchymal tumors.

Authors:  Shogo Tajima; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

10.  Clinicopathologic and molecular features of six cases of phosphaturic mesenchymal tumor.

Authors:  Lulu Sun; Carina Dehner; Jason Kenney; Samantha M McNulty; Xiaopei Zhu; John D Pfeifer; Horacio M Maluf; John S A Chrisinger
Journal:  Virchows Arch       Date:  2020-11-05       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.